Fintel reports that on November 21, 2024, Morgan Stanley initiated coverage of Apellis Pharmaceuticals (NasdaqGS:APLS) with a Equal-Weight recommendation.
Analyst Price Forecast Suggests 70.68% Upside
As of November 21, 2024, the average one-year price target for Apellis Pharmaceuticals is $46.92/share. The forecasts range from a low of $20.20 to a high of $81.90. The average price target represents an increase of 70.68% from its latest reported closing price of $27.49 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Apellis Pharmaceuticals is 579MM, a decrease of 19.11%. The projected annual non-GAAP EPS is -2.73.
What is the Fund Sentiment?
There are 597 funds or institutions reporting positions in Apellis Pharmaceuticals. This is an decrease of 9 owner(s) or 1.49% in the last quarter. Average portfolio weight of all funds dedicated to APLS is 0.20%, an increase of 15.50%. Total shares owned by institutions increased in the last three months by 3.90% to 133,613K shares. 
The put/call ratio of APLS is 0.30, indicating a bullish outlook.
What are Other Shareholders Doing?
Wellington Management Group Llp holds 15,567K shares representing 12.51% ownership of the company. In its prior filing, the firm reported owning 16,389K shares , representing a decrease of 5.28%. The firm decreased its portfolio allocation in APLS by 90.18% over the last quarter.
EcoR1 Capital holds 11,891K shares representing 9.56% ownership of the company. In its prior filing, the firm reported owning 11,607K shares , representing an increase of 2.38%. The firm decreased its portfolio allocation in APLS by 13.83% over the last quarter.
Avoro Capital Advisors holds 11,111K shares representing 8.93% ownership of the company. No change in the last quarter.
VGHCX - Vanguard Health Care Fund Investor Shares holds 10,089K shares representing 8.11% ownership of the company. In its prior filing, the firm reported owning 9,503K shares , representing an increase of 5.80%. The firm decreased its portfolio allocation in APLS by 10.94% over the last quarter.
BlackRock holds 6,192K shares representing 4.98% ownership of the company.
Apellis Pharmaceuticals Background Information
(This description is provided by the company.)
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
